Nicolas Margot

4.3k total citations · 1 hit paper
73 papers, 2.9k citations indexed

About

Nicolas Margot is a scholar working on Virology, Infectious Diseases and Molecular Biology. According to data from OpenAlex, Nicolas Margot has authored 73 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 69 papers in Virology, 68 papers in Infectious Diseases and 7 papers in Molecular Biology. Recurrent topics in Nicolas Margot's work include HIV Research and Treatment (69 papers), HIV/AIDS drug development and treatment (68 papers) and HIV/AIDS Research and Interventions (43 papers). Nicolas Margot is often cited by papers focused on HIV Research and Treatment (69 papers), HIV/AIDS drug development and treatment (68 papers) and HIV/AIDS Research and Interventions (43 papers). Nicolas Margot collaborates with scholars based in United States, France and Italy. Nicolas Margot's co-authors include Michael D. Miller, Andrew Cheng, Lisa K. Naeger, Kirsten White, Christian Callebaut, Michael D. Miller, Lijie Zhong, Damian J. McColl, Martin S. Rhee and Julie M. Cherrington and has published in prestigious journals such as New England Journal of Medicine, PLoS ONE and Clinical Infectious Diseases.

In The Last Decade

Nicolas Margot

71 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection

2022 164 citations Sorana Segal‐Maurer, Edwin DeJesus et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nicolas Margot United States	33	2.7k	2.5k	488	413	193	73	2.9k
Johan Vingerhoets United States	22	2.4k 0.9×	2.1k 0.8×	556 1.1×	318 0.8×	176 0.9×	46	2.6k
Marc Wirden France	25	1.9k 0.7×	1.7k 0.7×	317 0.6×	324 0.8×	101 0.5×	105	2.1k
Javier O Morales-Ramirez United States	11	1.8k 0.7×	1.5k 0.6×	231 0.5×	232 0.6×	383 2.0×	13	1.9k
Daniela Moïsi Canada	27	2.4k 0.9×	2.2k 0.9×	654 1.3×	245 0.6×	154 0.8×	68	2.6k
Bernard Masquelier France	30	2.1k 0.8×	1.9k 0.8×	399 0.8×	181 0.4×	140 0.7×	85	2.3k
Annemarie M. J. Wensing Netherlands	13	1.6k 0.6×	1.4k 0.6×	333 0.7×	214 0.5×	87 0.5×	23	1.8k
Kirsten White United States	33	3.8k 1.4×	3.1k 1.3×	635 1.3×	658 1.6×	761 3.9×	87	4.1k
Michael E. Abram United States	20	1.1k 0.4×	751 0.3×	431 0.9×	344 0.8×	276 1.4×	36	1.6k
Cindy Vavro United States	15	1.4k 0.5×	1.1k 0.5×	284 0.6×	173 0.4×	308 1.6×	26	1.5k
Leslie Jonas United States	10	1.7k 0.6×	1.7k 0.7×	486 1.0×	142 0.3×	234 1.2×	11	2.2k

Countries citing papers authored by Nicolas Margot

Since Specialization

Citations

This map shows the geographic impact of Nicolas Margot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nicolas Margot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nicolas Margot more than expected).

Fields of papers citing papers by Nicolas Margot

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nicolas Margot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nicolas Margot. The network helps show where Nicolas Margot may publish in the future.

Co-authorship network of co-authors of Nicolas Margot

This figure shows the co-authorship network connecting the top 25 collaborators of Nicolas Margot. A scholar is included among the top collaborators of Nicolas Margot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nicolas Margot. Nicolas Margot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Demirdjian, Sally, et al.. (2025). Phenotypic Characterization of Replication‐Impaired Lenacapavir‐Resistant HIV Clinical Isolates. Journal of Medical Virology. 97(4). e70340–e70340. 2 indexed citations

Ogbuagu, Onyema, Jean‐Michel Molina, Ploenchan Chetchotisakd, et al.. (2024). Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People with Multidrug-Resistant HIV-1: Week 104 Results of a Phase 2/3 Trial. Clinical Infectious Diseases. 80(3). 566–574. 14 indexed citations

Cox, Stephanie, Nicolas Margot, & Christian Callebaut. (2023). Antiviral activity of tenofovir alafenamide (TAF) against HIV‐1 clinical isolates harboring K65R. Journal of Medical Virology. 95(4). e28723–e28723. 3 indexed citations

Margot, Nicolas, et al.. (2023). Rapid HIV‐1 genotyping assay for the detection of capsid mutations. Journal of Medical Virology. 95(12). e29292–e29292. 4 indexed citations

Manceau, Gilles, Nicolas Margot, Jérémy Augustin, et al.. (2019). YpN0 rectal cancer patients with sterilized lymph nodes after neoadjuvant chemoradiotherapy are of greater risk of recurrence. Digestive and Liver Disease. 52(2). 214–220. 3 indexed citations

Cox, Stephanie, Nicolas Margot, Michael D. Miller, & Christian Callebaut. (2018). Antiviral Activity of Tenofovir Alafenamide Against HIV-1 Subtypes and Emergence of K65R. AIDS Research and Human Retroviruses. 34(5). 456–458. 2 indexed citations

Margot, Nicolas, Stephanie Cox, Moupali Das, et al.. (2018). Rare emergence of drug resistance in HIV-1 treatment-naïve patients receiving elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide for 144 weeks. Journal of Clinical Virology. 103. 37–42. 16 indexed citations

DeJesus, Edwin, Sorana Segal‐Maurer, Moti Ramgopal, et al.. (2018). Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment. AIDS Research and Human Retroviruses. 34(4). 337–342. 67 indexed citations

Abram, Michael E., Renee R. Ram, Nicolas Margot, et al.. (2017). Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome. PLoS ONE. 12(2). e0172206–e0172206. 18 indexed citations

10.

Margot, Nicolas, Pamela Wong, Rima Kulkarni, et al.. (2017). Commonly Transmitted HIV-1 Drug Resistance Mutations in Reverse-Transcriptase and Protease in Antiretroviral Treatment–Naive Patients and Response to Regimens Containing Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide. The Journal of Infectious Diseases. 215(6). 920–927. 31 indexed citations

11.

Margot, Nicolas, Yang Liu, Michael D. Miller, & Christian Callebaut. (2016). High resistance barrier to tenofovir alafenamide is driven by higher loading of tenofovir diphosphate into target cells compared to tenofovir disoproxil fumarate. Antiviral Research. 132. 50–58. 24 indexed citations

12.

Margot, Nicolas, Kathryn M. Kitrinos, Marshall W. Fordyce, et al.. (2016). Rare emergence of drug resistance in HIV-1 treatment -naïve patients after 48 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide. HIV Clinical Trials. 17(2). 78–87. 12 indexed citations

13.

Elion, Richard, Jean‐Michel Molina, José Ramón Arribas, et al.. (2013). A Randomized Phase 3 Study Comparing Once-Daily Elvitegravir With Twice-Daily Raltegravir in Treatment-Experienced Subjects With HIV-1 infection. JAIDS Journal of Acquired Immune Deficiency Syndromes. 63(4). 494–497. 33 indexed citations

14.

McColl, Damian J., Nicolas Margot, Shanshan Chen, et al.. (2011). Reduced Emergence of the M184V/I Resistance Mutation When Antiretroviral-Naïve Subjects Use Emtricitabine Versus Lamivudine in Regimens Composed of Two NRTIs Plus the NNRTI Efavirenz. HIV Clinical Trials. 12(2). 61–70. 20 indexed citations

15.

Feng, Joy Y., Florence Myrick, Nicolas Margot, et al.. (2006). Virologic and Enzymatic Studies Revealing the Mechanism of K65R- and Q151M-Associated HIV-1 Drug Resistance Towards Emtricitabine and Lamivudine. Nucleosides Nucleotides & Nucleic Acids. 25(1). 89–107. 20 indexed citations

16.

White, Kirsten, Nicolas Margot, James Chen, et al.. (2005). A combination of decreased NRTI incorporation and decreased excision determines the resistance profile of HIV-1 K65R RT. AIDS. 19(16). 1751–1760. 65 indexed citations

17.

McColl, Damian J., Nicolas Margot, Michael Wulfsohn, et al.. (2004). Patterns of Resistance Emerging in HIV-1 From Antiretroviral-Experienced Patients Undergoing Intensification Therapy With Tenofovir Disoproxil Fumarate. JAIDS Journal of Acquired Immune Deficiency Syndromes. 37(3). 1340–1350. 40 indexed citations

18.

Margot, Nicolas, et al.. (2002). Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF. AIDS. 16(9). 1227–1235. 126 indexed citations

19.

Palmer, Sarah, et al.. (2001). Tenofovir, Adefovir, and Zidovudine Susceptibilities of Primary Human Immunodeficiency Virus Type 1 Isolates with Non-B Subtypes or Nucleoside Resistance. AIDS Research and Human Retroviruses. 17(12). 1167–1173. 37 indexed citations

20.

Miller, Michael D., Nicolas Margot, Patrick D. Lamy, et al.. (2001). Adefovir and Tenofovir Susceptibilities of HIV-1 After 24 to 48 Weeks of Adefovir Dipivoxil Therapy: Genotypic and Phenotypic Analyses of Study GS-96-408. JAIDS Journal of Acquired Immune Deficiency Syndromes. 27(5). 450–458. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact